Myriad Genetics (MYGN) Misses Q1 EPS by 2c; Maintains Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
November 1, 2016 4:05 PM EDTTotal Revenues of $177.5 MillionAdjusted EPS of $0.23 and Diluted EPS of ($0.02)Company Maintains Fiscal Year 2017 Financial Guidance and Issues Fiscal Second-Quarter 2017 Financial Guidance
SALT LAKE CITY, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal first-quarter 2017, provided an update on recent business highlights, Â maintained its fiscal year 2017 financial guidance and issued fiscal second-quarter 2017 financial guidance.Â
"We were pleased with the first quarter as our hereditary cancer business returned to more normal... More
